



CASE D0299 NP

**CERTIFICATE OF MAILING**

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\_\_\_\_\_  
Keith R. Lange  
Type or print name

\_\_\_\_\_  
Signature

\_\_\_\_\_  
March 19, 2004  
Date

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF

WANG ET AL.

APPLICATION NO: 10/645,190

FILED: AUGUST 21, 2003

FOR: METHODS FOR PREVENTING ISCHEMIC BRAIN INJURY

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
(609) 252-3883

  
Keith R. Lange  
Attorney for Applicants  
Reg. No. 44,201

Date: March 19, 2004

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOCKET NO.  
 D0299 NP  
 APPLICATION NO.  
 10/645,190  
 APPLICANT  
 WANG ET AL.  
 FILING DATE  
 AUGUST 21, 2003

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Alessandrini, A. et al., "MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia", Proc. Nat'l. Acad. Sci., USA, Vol. 96, No. 22, pp. 12866-12869 (1999)
AS	Barone, F.C. et al., "SB 239063, a Second-Generation p38 Mitogen-Activated Protein Kinase Inhibitor, Reduces Brain Injury and Neurological Deficits in Cerebral Focal Ischemia", The Journal of Pharmacology and Experimental Therapeutics, Vol. 296, No. 2, pp. 312-321 (2001)
AT	Cano, E. et al., "Parallel signal processing among mammalian MAPKs", Trends Biochem. Sci., Vol. 20, pp. 117-122 (1995)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
D0299 NP  
APPLICATION NO.  
10/645,190  
APPLICANT  
WANG ET AL.  
FILING DATE  
AUGUST 21, 2003

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

2AA	Huang, C.-K. et al., "LSP1 Is the Major Substrate for Mitogen-activated Protein Kinase-activated Protein Kinase 2 in Human Neutrophils", The Journal of Biological Chemistry, Vol. 272, No. 1, pp. 17-19 (1997)
2AB	Irving, E.A. et al., "Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat", Molecular Brain Research, Vol. 77, pp. 65-75 (2000)
2AC	Kotlyarov, A. et al., "MAPKAP kinase 2 is essential for LPS-induced TNF- $\alpha$ biosynthesis", Nature Cell Biology, Vol. 1, pp. 94-97 (1999)
2AD	Rouse, J. et al., "A Novel Kinase Cascade Triggered by Stress and Heat Shock That Stimulates MAPKAP Kinase-2 and Phosphorylation of the Small Heat Shock Proteins", Cell, Vol. 78, pp. 1027-1037 (1994)
2AE	Sugino, T. et al., "Activation of Mitogen-Activated Protein Kinases after Transient Forebrain Ischemia in Gerbil Hippocampus", The Journal of Neuroscience, Vol. 20, No. 12, pp. 4506-4514 (2000)
2AF	Thomas, G. et al., "Participation of a stress-activated protein kinase cascade in the activation of tyrosine hydroxylase in chromaffin cells", Eur. J. Biochem., Vol. 247, pp. 1180-1189 (1997)
2AG	Wang, H. et al., "Differential Regulation of IL-1 $\beta$ and TNF- $\alpha$ RNA Expression by MEK1 Inhibitor after Focal Cerebral Ischemia in Mice", Biochemical and Biophysical Research Communications, Vol. 286, pp. 869-874 (2001)
2AH	Wang, X. et al., "Role of Immune and Inflammatory Mediators in CNS Injury", Drug News Perspect, Vol. 13, No. 3, pp. 133-140 (2000)
2AI	Werz, O. et al., "Arachidonic Acid Promotes Phosphorylation of 5-Lipoxygenase at Ser-271 by MAPK-activated Protein Kinase 2 (MK2)", The Journal of Biological Chemistry, Vol. 277, No. 17, pp. 14793-14800 (2002)
2AJ	Zhang, R.L. et al., "A rat model of focal embolic cerebral ischemia", Brain Research, Vol. 766, pp. 83-92 (1997)
AK	
AL	
AM	
AN	

**EXAMINER****DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.